Arcus Biosciences, Inc.
RCUS· NYSE
Released May 6, 2025, after the close
10-Q filed May 6, 2025, 36 days after period end · 0001724521-25-000063
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $8.00M | $10.00M | $25.00M | $18.00M |
| Net Income | -$112.00M | -$4.00M | -$80.00M | -$68.00M |
| EPS Diluted |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| -$1.14 |
| -$0.05 |
| -$1.09 |
| -$0.96 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.